Cidara Therapeutics (NASDAQ:CDTX – Get Free Report)‘s stock had its “strong-buy” rating reiterated by stock analysts at WBB Securities in a note issued to investors on Thursday, Benzinga reports. They currently have a $40.00 price target on the biotechnology company’s stock. WBB Securities’ price target would indicate a potential upside of 207.69% from the stock’s […]
Consolidated financial statements. In the preparation of the consolidated financial statements, amounts resulting from transactions between consolidated companies, including the equity.
ContraFect (NASDAQ:CFRX – Get Rating) was upgraded by analysts at WBB Securities to a “strong-buy” rating in a research note issued on Wednesday, Stock Target Advisor reports. The firm presently has a $7.00 target price on the biotechnology company’s stock. WBB Securities’ price objective points to a potential upside of 104.68% from the company’s current […]